Tag: TCT 2025
Music therapy improves patient experience during PCI and shows promise for fine tuning cardiovascular parameters
Playing music to patients undergoing percutaneous coronary intervention (PCI) may reduce stress ...
FAME 3: PCI shown to be more cost effective than CABG
Economic analysis of the FAME 3 trial, comparing fractional flow reserve (FFR)-guided percutaneo...
Cardiovascular News – Issue 79 – November 2025 (US)
In this issue:
Get up to date on late-breaking trials from the Transcatheter Cardiovascular The...
Cardiovascular News – Issue 79 – November 2025 (OUS)
In this issue:
Get up to date on late-breaking trials from the Transcatheter Cardiovascular The...
Native vessel PCI “no longer the default strategy” for patients with previous CABG
Should interventionalists prioritise native or saphenous vein graft percutaneous coronary interven...
Alteplase fails to impact outcomes in STEMI patients with high thrombus burden
Low-dose intracoronary fibrinolysis infusion during primary percutaneous coronary intervention (PC...
Tendyne system shows promise in patients with mitral annular calcification
A trial of transcatheter mitral valve replacement (TMVR) with the Tendyne system (Abbott) led to s...
Transseptal TMVR system shows promise in patients unsuited for surgery or TEER
Results of a pivotal clinical trial evaluating the safety and efficacy of a fully percutaneous tra...
Latest data “reassuring” on safety and effectiveness of transcatheter tricuspid interventions
Analysis of data from the Society of Thoracic Surgeons (STS) and American College of Cardiology (A...
Interim RAPID-PE study reveals ‘excellent’ safety data in first 50 patients
Prespecified interim analysis data from the first 50 patients in RAPID-PE have demonstrated "exc...
TCT 2025: Deferring treatment of non-culprit lesions “remains an option” for STEMI in multivessel disease
New data suggest that interventionalists can safely opt to defer the treatment of non-culprit le...
TCT 2025: Coronary bioadaptor shows reduction in events compared to DES at two years
Latest clinical results for the DynamX coronary bioadaptor (Elixir Medical) demonstrate that the...
TCT 2025: TAVI continues to match up to surgery at seven years in PARTNER 3 trial
Latest results from the PARTNER 3 trial, comparing transcatheter aortic valve implantation (TAVI...
TCT 2025: “Site-less” trial opens window on prevalence of heart valve disease across USA
A “site-less” trial that recruited subjects at pharmacies across the USA to screen for valvular ...
TCT 2025: STORM-PE finds mechanical thrombectomy superior to anticoagulation alone
The use of mechanical thrombectomy, specifically computer-assisted vacuum thrombectomy (CAVT) us...
TCT 2025: Trials find comparable outcomes for IVL alternatives in calcified coronary disease
Cutting balloon angioplasty and the use of a super-high-pressure non-compliant balloon have been...
TCT 2025: Selution SLR meets non-inferiority in de novo and in-stent restenosis trials
Cordis has announced results from the SELUTION DeNovo and SELUTION4ISR trials, presented during ...
Smart implant for pressure-guided heart failure decongestion wins TCT 2025 Shark Tank prize
Relief Cardiovascular—developer of a smart implant designed to haemodynamically monitor and trea...
Medtronic launches “extra stiff” TAVI guidewire
Medtronic has announced the launch of the Stedi Extra Support guidewire, designed to enhance sta...
